CTMX

CytomX Therapeutics (CTMX)

About CytomX Therapeutics (CTMX)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Details

Daily high

$1.16

Daily low

$1.10

Price at open

$1.15

52 Week High

$5.85

52 Week Low

$1.04

Market cap

89.8M

Dividend yield

0.00%

Volume

292,760

Avg. volume

754,820

P/E ratio

8.26

CytomX Therapeutics News